Health Kick Podcast: Prescient Therapeutics an emerging global leader in the next generation of personalised cancer therapies.
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up...
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up...
It’s the quarterly season again as the ASX market announcements page becomes increasingly flooded with...
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up...
Prescient Therapeutics is hoping to follow in the footsteps of Neuren Pharmaceuticals after positive results...
Telix Pharma (ASX:TLX) announced the US FDA has approved a supplementary New Drug Application (sNDA) for Illuccix,...
The granting of an Orphan Drug Designation for PTX-100 gives Prescient guaranteed market exclusivity of...
Stockhead’s Prepped and Primed video series is a yearly wrap up address from company leaders...
Stockhead’s Year in Review video series is a yearly wrap up address from company leaders...
It’s quarterlies season again as the ASX market announcements page becomes increasingly flooded with earnings...
Prescient’s PTX-100 Phase 1b study shows encouraging responses on a patient population that is notoriously...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.